Back to News
Market Impact: 0.15
Oncolytics Expands Pelareorep Patent Strategy With New Method-of-Use Filings
Source: Nasdaq
Patents & Intellectual PropertyHealthcare & Biotech
Oncolytics Biotech (ONCY), a clinical-stage immunotherapy company, reported progress on new method-of-use patent applications and plans to expand its portfolio with composition-of-matter protection. The article text is truncated before specifying the subject of that protection or further details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
ONCY0.20
More News
- J&J's 6% slide on an imperfect quarter is a gift to prospective buyers
- UnitedHealth Group tops estimates, hikes profit outlook as insurer manages high medical costs
- J&J beats earnings estimates; Middle East conflict weighs on medical-device sales
- Rhythm Pharmaceuticals launches IMCIVREE in Japan for obesity
- Liquidia (NASDAQ:LQDA) CMO Rajeev Saggar disposes of $262,528 in stock
- Delaware jury awards Qualcomm $2 in damages, finds Arm breached license agreement